You are here

  • Home
  • Archive
  • Volume 80, Issue 5
  • Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al

Authors

  • Alexis Mathian Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France PubMed articlesGoogle scholar articles
  • Zahir Amoura Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Alexis Mathian, Internal Medicine, University Hospital Pitié Salpêtrière, 75651 Paris, France; alexis.mathian{at}aphp.fr
View Full Text

Citation

Mathian A, Amoura Z
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al
Annals of the Rheumatic Diseases 2021;80:e70.

Publication history

  • Received July 21, 2020
  • Accepted July 22, 2020
  • First published July 31, 2020.
Online issue publication 
April 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage